Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising

Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising